Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial

Leukemia · Published 2026-07-24 · DOI 10.1038/s41375-026-03009-x

Free full text

Authors (23)

Hagop Kantarjian, Michael Deininger, Jane F. Apperley, Christopher Kevin Arthur, Charles Chuah, Andreas Hochhaus, Hugues de Lavallade, Jeffrey H. Lipton, Elza Lomaia, James McCloskey, Lori Maness, Michael Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, Bo Chao, Alexander Vorog, L. Evan Reddick, Niti Patel, Meliessa Hennessy, Tammie Yeh, Jorge Cortes

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kantarjian, H., Deininger, M., Apperley, J., et al. (2026). Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial. Leukemia. https://doi.org/10.1038/s41375-026-03009-x

Related articles

• Treatment of adult acute lymphoblastic leukemia—a therapeutic revolution in the making · Blood Cancer Journal · 2026 · Cites or is cited by this article
• Evolutionary considerations for risk stratification in TP53-variant myeloproliferative neoplasms · Leukemia · 2026 · Same journal
• Rbm5 sustains leukemia stem cells through a Myc-driven transcriptional circuitry · Leukemia · 2026 · Same journal
• Cohesin haploinsufficiency and inv(16) cooperate to reinforce Fli1 gene transcriptional programs during acute myeloid leukemia initiation and maintenance · Leukemia · 2026 · Same journal
• Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis · Leukemia · 2026 · Same journal
• FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia · Leukemia · 2026 · Same journal
• IKZF1N159S is associated with adverse outcomes in patients with myelodysplastic neoplasms · Leukemia · 2026 · Same journal
• Tumor molecular age acceleration is associated with early progression in diffuse large B-cell lymphoma · Leukemia · 2026 · Same journal
• Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry · Leukemia · 2026 · Same journal
• Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms · Leukemia · 2026 · Same journal